Clinical Trial Update: Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating perioperative tislelizumab with nab-paclitaxel for muscle-invasive urothelial bladder cancer shows an ongoing study with unclear status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Muscle Invasive Bladder Cancer, Urothelial Carcinoma | Phase 2 | Status: UNKNOWN